Hirofumi Hamano
Papers
1
Total Citations
17
H-Index
1
About
Hirofumi Hamano is a dedicated pharmacoepidemiologist whose research focuses on the safety profiles of cancer therapies, particularly concerning prostate cancer treatment. His most cited work, "Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects" (2021, 17 citations), critically analyzes global adverse event data from 2002 to 2018, a period when prostate cancer cases rose from 679,023 to 1,276,106 worldwide. Hamano's major contribution lies in identifying and quantifying the risk of interstitial lung disease linked to antiandrogen therapies—a serious complication often overlooked in clinical practice. By leveraging spontaneous reporting databases, he provides real-world evidence that complements clinical trial findings, helping oncologists weigh treatment risks more carefully. His work underscores the importance of pharmacovigilance in an era of expanding pharmacological options for prostate cancer, including alongside standard treatments like prostatectomy and radiation. Hamano’s research has significant implications for patient safety, offering actionable insights that guide safer prescribing. His meticulous approach to mining large-scale adverse event data marks him as a key voice in drug safety research, bridging the gap between clinical efficacy and real-world harm.
Research Focus
Key Achievements
Top Papers
- 1